Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate
Table 2
Loteprednol etabonate: summary of randomized, controlled, clinical safety and efficacy studies in postoperative inflammation.
Treatment duration and study treatments
Efficacy
Safety
Reference
2 weeks LE 0.5% () versus placebo ()
(i) Resolution of ACI at final visit: 64% versus 29% ( versus placebo) (ii) Treatment failure rate: 6% versus 30% ( versus placebo) (iii) Investigator global assessment of treatment effect ( versus placebo) (iv) Grade 0 (no pain) at final visit: 85% versus 54% ()
IOP (≥10 mm Hg) for LE for placebo Mean IOP decreased in both groups ≥1 AE: 58% versus 80% ()
(i) Resolution of ACI at final visit: 55% versus 28% () (ii) Treatment failure rate: 7% versus 32% ( versus placebo) (iii) Investigator global assessment of treatment effect ( versus placebo) (iv) Grade 0 (no pain) at final visit: 83% versus 59% ()
IOP ≥10 mm Hg) for LE for placebo Mean IOP decreased in both groups ≥1 AE: 54% versus 75% ()
2 weeks LE 0.5% ointment () versus vehicle () [2 studies]
(i) Resolution of ACI at day 8: 27.7% versus 12.5% () (ii) Grade 0 (no pain) at day 8: 75.5% versus 43.1% () (iii) Need for rescue medication: 27.7% versus 63.8% ()
↑ IOP (≥10 mm Hg): for LE for vehicle Mean IOP decreased in both groups Mean IOP decreased in both groups ≥1 AE: 47.2% versus 78.0% ()